DE602006021044D1 - Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren - Google Patents
Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitorenInfo
- Publication number
- DE602006021044D1 DE602006021044D1 DE602006021044T DE602006021044T DE602006021044D1 DE 602006021044 D1 DE602006021044 D1 DE 602006021044D1 DE 602006021044 T DE602006021044 T DE 602006021044T DE 602006021044 T DE602006021044 T DE 602006021044T DE 602006021044 D1 DE602006021044 D1 DE 602006021044D1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- compounds
- nr15b
- 6alkyl
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- -1 C1-2fluoroalkyl Chemical group 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72159705P | 2005-09-29 | 2005-09-29 | |
| PCT/GB2006/003626 WO2007036733A1 (en) | 2005-09-29 | 2006-09-29 | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602006021044D1 true DE602006021044D1 (de) | 2011-05-12 |
Family
ID=37685723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602006021044T Active DE602006021044D1 (de) | 2005-09-29 | 2006-09-29 | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090131431A1 (de) |
| EP (2) | EP1940836A1 (de) |
| JP (2) | JP2009510044A (de) |
| AT (1) | ATE503756T1 (de) |
| DE (1) | DE602006021044D1 (de) |
| ES (1) | ES2363795T3 (de) |
| WO (2) | WO2007036734A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
| GB0614570D0 (en) * | 2006-07-21 | 2006-08-30 | Glaxo Group Ltd | Compounds |
| PL2046787T3 (pl) | 2006-08-01 | 2011-10-31 | Glaxo Group Ltd | Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 |
| SI2124944T1 (sl) * | 2007-03-14 | 2012-05-31 | Ranbaxy Lab Ltd | Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze |
| CN101687810A (zh) | 2007-04-26 | 2010-03-31 | 武田药品工业株式会社 | 双环化合物及其药物用途 |
| EP2249830A4 (de) * | 2008-02-06 | 2012-07-18 | Glaxo Group Ltd | Duale pharmakophoren pde4-muscarinische antagonisten |
| WO2009100169A1 (en) * | 2008-02-06 | 2009-08-13 | Glaxo Group Limited | Dual pharmacophores - pde4-muscarinic antagonistics |
| CA2735956A1 (en) * | 2008-09-19 | 2010-04-29 | Ranbaxy Laboratories Limited | Phosphodiestarase inhibitors |
| US8470835B2 (en) | 2009-01-13 | 2013-06-25 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase |
| SG183855A1 (en) * | 2010-03-16 | 2012-10-30 | Merck Patent Gmbh | Morpholinylquinazolines |
| US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
| US20140113898A1 (en) * | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| EP2574607A1 (de) * | 2011-09-06 | 2013-04-03 | F. Hoffmann-La Roche AG | PDE 10-Modulatoren |
| US9243001B2 (en) | 2013-03-15 | 2016-01-26 | Epizyme, Inc. | Substituted benzene compounds |
| WO2014172044A1 (en) * | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| US9011934B2 (en) | 2013-06-14 | 2015-04-21 | SatisPharma, LLC | Multi-purpose anti-itch treatment |
| CN105940002B (zh) | 2014-02-03 | 2018-09-25 | 生命医药公司 | ROR-γ的二氢吡咯并吡啶抑制剂 |
| DE102014009164A1 (de) * | 2014-06-03 | 2015-12-03 | Herbalist & Doc Gesundheitsgesellschaft Mbh | Silikonölhaltige nasal anzuwendende Formulierungen |
| TWI675032B (zh) | 2014-10-14 | 2019-10-21 | 美商維它藥物公司 | ＲＯＲ-γ之二氫吡咯并吡啶抑制劑 |
| US9452178B1 (en) | 2014-10-22 | 2016-09-27 | SatisPharma, LLC | Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| BR112019012322A2 (pt) | 2016-12-20 | 2019-11-19 | Syngenta Participations Ag | n-ciclobutil-tiazol-5-carboxamidas com atividade nematicida |
| AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| BR112020001246A2 (pt) | 2017-07-24 | 2020-07-21 | Vitae Pharmaceuticals, Llc | inibidores de rory |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| AR112346A1 (es) * | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| EP4093385A4 (de) * | 2020-01-23 | 2024-02-07 | Myoforte Therapeutics Inc. | Pgdh-inhibitoren und verfahren zum herstellen und verwenden |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05002887A (es) * | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa. |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US20090131431A1 (en) * | 2005-09-29 | 2009-05-21 | Christopher David Edlin | Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors |
-
2006
- 2006-09-29 US US12/067,990 patent/US20090131431A1/en not_active Abandoned
- 2006-09-29 ES ES06779578T patent/ES2363795T3/es active Active
- 2006-09-29 US US12/067,994 patent/US20080255186A1/en not_active Abandoned
- 2006-09-29 JP JP2008532874A patent/JP2009510044A/ja active Pending
- 2006-09-29 JP JP2008532873A patent/JP5323484B2/ja not_active Expired - Fee Related
- 2006-09-29 WO PCT/GB2006/003627 patent/WO2007036734A1/en active Application Filing
- 2006-09-29 EP EP06779579A patent/EP1940836A1/de not_active Withdrawn
- 2006-09-29 WO PCT/GB2006/003626 patent/WO2007036733A1/en active Application Filing
- 2006-09-29 EP EP06779578A patent/EP1940835B1/de active Active
- 2006-09-29 AT AT06779578T patent/ATE503756T1/de not_active IP Right Cessation
- 2006-09-29 DE DE602006021044T patent/DE602006021044D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1940835B1 (de) | 2011-03-30 |
| JP5323484B2 (ja) | 2013-10-23 |
| JP2009510044A (ja) | 2009-03-12 |
| EP1940836A1 (de) | 2008-07-09 |
| US20090131431A1 (en) | 2009-05-21 |
| EP1940835A1 (de) | 2008-07-09 |
| WO2007036733A1 (en) | 2007-04-05 |
| WO2007036734A1 (en) | 2007-04-05 |
| JP2009510043A (ja) | 2009-03-12 |
| US20080255186A1 (en) | 2008-10-16 |
| ES2363795T3 (es) | 2011-08-16 |
| ATE503756T1 (de) | 2011-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503756T1 (de) | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren | |
| RS52042B (en) | FUNGICID MIXTURES | |
| GT200600283A (es) | COMPUESTOS DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA LA MODULACIÓN DE LA beta-SECRETASA | |
| RS52216B (en) | UNITS AND METHODS FOR FXR MODULATION | |
| DE60330362D1 (de) | Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) | |
| RS54878B1 (sr) | Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril | |
| WO2007109456A3 (en) | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists | |
| DE60327443D1 (de) | Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf) | |
| EA200870409A1 (ru) | Антагонисты киназы pi3 | |
| CL2009000576A1 (es) | Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide. | |
| TW200744994A (en) | Insecticidal 3-acylaminobenzanilides | |
| PE20051061A1 (es) | 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS | |
| PE20120814A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| EA200700188A1 (ru) | Производные замещенного 2-алкилхиназолинона как ингибиторы parp | |
| NO20070122L (no) | Quinazolinonderivater anvendelige som vanilloidantagonister | |
| EA200802380A1 (ru) | Совместные кристаллы пирролидинонов | |
| EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
| WO2008053044A3 (de) | Hetarylcarbonsäure-n-(biphen-2-yl)amid-verbindungen | |
| PE20140226A1 (es) | Compuestos de triazolopiridina | |
| EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| EA201001348A1 (ru) | Пирролопиримидинкарбоксамиды | |
| CL2007002349A1 (es) | Compuestos derivados de pirazolo[3,4-b]piridina; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de una enfermedad inflamatoria y/o alergica, tal como epoc, asma y rinitis. | |
| CL2009001146A1 (es) | Compuestos derivados de 5-(5-(2-(3,5-bis(trifluorometil)fenil)-n,2-dimetilpropanoamida)-4-(4-fluoro-2-metilfenil)piridin-2-il)pirrolidin-2-carboxamida, antagonistas de los receptores nk-1; composicion farmaceutica; y uso del compuesto para el tratamiento de la depresion; ansiedad, trastornos del sueño o emesis. | |
| WO2006041830A3 (en) | Cgrp receptor antagonists |